Assessment of Colchicine efficacy in treatment of chronic hepatitis B

A comparative evaluation of combination therapy of Lamivudine and Colchicine comparing with Lamivudine and placebo in clinical and laboratory improvement of chronic hepatitis B

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138807112539N1

Enrollment

100

Registered

2009-11-08

Start date

2009-07-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic viral hepatitis B. Chronic viral hepatitis B

Interventions

Intervention 1: Lamivudine, 100 mg daily and Colchicine 0.5mg daily for 6 months. Intervention 2: Lamivudine 100 mg daily and placebo once daily for 6 months.

Treatment - Drugs

Lamivudine, 100 mg daily and Colchicine 0.5mg daily for 6 months

Lamivudine 100 mg daily and placebo once daily for 6 months

Eligibility

Sex/Gender

All

Age

15 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: positive HBS Ag, confirmed chronic hepatitis B, ALT level at least twofold of normal range Exclusion criteria: positive HCV Ab, positive HIV Ab, Alcohol abuse, Presence of auto immune hepatitis, metabolic liver disease, right cardiac failure or pulmonary hypertension, low compliance, allergic reaction to drugs or sever side effect of drugs, presence of decompensate cirrhosis (PT>20 sec and ALb<3 gr/dl)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Treatment of chronic hepatitis B. Timepoint: One month before intervention and one month after intervention. Method of measurement: Laboratory measurement of serum ALT- Albumin-bilirubin and PT.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Amir Hassanpour

Arak University of Medical Sciences

drhassanpor@arakmu.ac.ir+98 86 1417 3608

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026